Directorio

We are doing this study to understand how environmental exposures may be involved in lung function. We want to find out how immune cells in the lungs are affected by irritants that are present in the environment.

We are doing this study to learn more about ATTR and its different variants and how they can can be better diagnosed, managed, and treated.

We are doing this study to find out if an experimental drug called NTLA-2001 (the study drug) is a safe and effective option for people with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study drug is made using the CRISPR-CaS9 gene editing system. The intent of the study drug that is being tested is to target the TTR gene and make it inactive.

We are doing this study to learn more about heart valve disease and its standard-of-care treatments, and we want to learn more about the safety and performance of the Corcym devices and accessories used for heart valve disease.

Duke will give patients three special inhalers called Airsupra to use when they need help breathing. Normally, patients use an inhaler called albuterol, but in this study, some patients will use Airsupra instead. After leaving the emergency room, the study team will check on patients at about 3, 6, and 12 weeks to see how they are doing and if they have any problems with their inhaler. Most check-ins will be by phone, but email may be used if the patient prefers or to make sure all information is collected.

In the first part of the study, some people will get a new medicine called maridebart cafraglutide. They will get small shots that slowly increase in amount over 16 weeks. Other people will get a fake medicine called a placebo, but the shots will look the same. After this first part, people who stay in the study can join the second part. In this part, everyone will get the real medicine for about 2 years. Doctors will keep checking to see how well the medicine works and if it is safe.

We are doing this study to find out if an experimental CAR-T cell therapy called MB-CART2019.1 (the study drug) may help eliminate cancer cells in patients who have relapsed or refractory DLBCL. The study drug will be combined with fludarabine and cyclophosphamide, which are both standard drugs used to treat DLBCL.

We are doing this study to learn more about the safety and performance of heart valve repair and replacement products made by Medtronic.